Members of the receptor for advanced glycation end products axis as potential therapeutic targets in patients with lupus nephritis

Lupus

Volumn 24, Issue 7, 2015, Pages 675-686

  Yu, S L ^a,b   Wong, C K ^a,c   Szeto, C C ^a   Li, E K ^a   Cai, Z ^a,c   Tam, Lai Shan ^a,c  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

HMGB1; inflammatory cytokines; lupus nephritis; mitogen activated protein kinase; RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; COMPLEMENT COMPONENT C3; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH MOBILITY GROUP B1 PROTEIN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12P70; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE P38; MYCOPHENOLATE MOFETIL; PREDNISOLONE; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR 9; ADVANCED GLYCATION END PRODUCT; AGER PROTEIN, HUMAN; BIOLOGICAL MARKER; CYTOKINE; HMGB1 PROTEIN, HUMAN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ACTIVITY; FEMALE; FLOW CYTOMETRY; HUMAN; INTRACELLULAR SIGNALING; LUPUS ERYTHEMATOSUS NEPHRITIS; MONOCYTE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; BLOOD; CASE CONTROL STUDY; GLOMERULONEPHRITIS; INFLAMMATION; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES;

ADULT; ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; BIOMARKERS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; CYTOKINES; FEMALE; FLOW CYTOMETRY; GLOMERULONEPHRITIS; GLYCOSYLATION END PRODUCTS, ADVANCED; HMGB1 PROTEIN; HUMANS; INFLAMMATION; INTERLEUKIN-6; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MIDDLE AGED; MONOCYTES; P38 MITOGEN-ACTIVATED PROTEIN KINASES;

EID: 84930833408     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203314559631     Document Type: Article

References (58)

1. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol. 2010 ; 28: 367-388
2. Lin L, Park S, Lakatta EG. RAGE signaling in inflammation and arterial aging. Front Biosci. 2009 ; 14: 1403-1413
3. Pouleur AC, le Polain de Waroux JB, Goffinet C, et al. Accuracy of the flow convergence method for quantification of aortic regurgitation in patients with central versus eccentric jets. Am J Cardiol. 2008 ; 102: 475-480
4. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest. 2001 ; 108: 949-955
5. Tam XH, Shiu SW, Leng L, et al. Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in Type 2 diabetes. Clin Sci. 2011 ; 120: 81-89
6. Hou FF, Ren H, Owen WF, et al. Enhanced expression of receptor for advanced glycation end products in chronic kidney disease. J Am Soc Nephrol. 2004 ; 15: 1889-1896
7. Abdulahad DA, Westra J, Limburg PC, Kallenberg CG, Bijl M. HMGB1 in systemic lupus erythematosus: Its role in cutaneous lesions development. Autoimmun Rev. 2010 ; 9: 661-665
8. Zickert A, Palmblad K, Sundelin B, et al. Renal expression and serum levels of high mobility group box 1 protein in lupus nephritis. Arthritis Res Ther. 2012 ; 14: R36 - R36
9. Urbonaviciute V, Voll RE. High-mobility group box 1 represents a potential marker of disease activity and novel therapeutic target in systemic lupus erythematosus. J Intern Med. 2011 ; 270: 309-318
10. Abdulahad DA, Westra J, Bijzet J. High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus. Arthritis Res Ther. 2011 ; 13: R71 - R71
11. Koyama H, Yamamoto H, Nishizawa Y. RAGE and soluble RAGE: Potential therapeutic targets for cardiovascular diseases. Mol Med. 2007 ; 13: 625-635
12. D'Adamo E, Giannini C, Chiavaroli V, et al. What is the significance of soluble and endogenous secretory receptor for advanced glycation end products in liver steatosis in obese prepubertal children?. Antioxid Redox Signal. 2011 ; 14: 1167-1172
13. Sunahori K, Yamamura M, Yamana J, et al. Increased expression of receptor for advanced glycation end products by synovial tissue macrophages in rheumatoid arthritis. Arthritis Rheum. 2006 ; 54: 97-104
14. Vazzana N, Santilli F, Cuccurullo C, Davi G. Soluble forms of RAGE in internal medicine. Intern Emerg Med. 2009 ; 4: 389-401
15. Harris HE, Andersson U, Pisetsky DS. HMGB1: A multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol. 2012 ; 8: 195-202
16. Wang H, Yang H, Tracey KJ. Extracellular role of HMGB1 in inflammation and sepsis. J Intern Med. 2004 ; 255: 320-331
17. Abeyama K, Stern DM, Ito Y, et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest. 2005 ; 115: 1267-1274
18. Zickert A, Palmblad K, Sundelin B, et al. Renal expression and serum levels of high mobility group box 1 protein in lupus nephritis. Arthritis Res Ther. 2012 ; 14: R36 - R36
19. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997 ; 40: 1725-1725
20. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992 ; 35: 630-640
21. Petri M, Genovese M, Engle E, Hochberg M. Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. Arthritis Rheum. 1991 ; 34: 937-944
22. Delles AM, Rittenhouse-Olson K, Morgan J, Oseroff AR. A simple method for the purification of human peripheral blood antigen presenting cells (dendritic cells, monocytes/macrophages, and B lymphocytes). Immunol Invest. 2002 ; 31: 233-245
23. Chavakis T, Bierhaus A, Al-Fakhri N, et al. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: A novel pathway for inflammatory cell recruitment. J Exp Med. 2003 ; 198: 1507-1515
24. Yu SL, Wong CK, Wong PT, et al. Down-regulated NOD2 by immunosuppressants in peripheral blood cells in patients with SLE reduces the muramyl dipeptide-induced IL-10 production. PLoS One. 2011 ; 6: e23855 - e23855
25. Wong CK, Cheung PF, Lam CW. Leptin-mediated cytokine release and migration of eosinophils: Implications for immunopathophysiology of allergic inflammation. Eur J Immunol. 2007 ; 37: 2337-2348
26. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest. 2001 ; 108: 949-955
27. Sparvero LJ, Asafu-Adjei D, Kang R, et al. RAGE (receptor for advanced glycation endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med. 2009 ; 7: 17-17
28. Li J, Schmidt AM. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem. 1997 ; 272: 16498-16506
29. Tanaka N, Yonekura H, Yamagishi S, et al. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem. 2000 ; 275: 25781-25790
30. Kokkola R, Sundberg E, Ulfgren AK, et al. High mobility group box chromosomal protein 1: A novel proinflammatory mediator in synovitis. Arthritis Rheum. 2002 ; 46: 2598-2603
31. Taniguchi N, Kawahara K, Yone K, et al. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum. 2003 ; 48: 971-981
32. Foell D, Kane D, Bresnihan B, et al. Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. Rheumatol. 2003 ; 42: 1383-1389
33. Hofmann MA, Drury S, Fu C, et al. RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/calgranulin polypeptides. Cell. 1999 ; 97: 889-901
34. Tydén H, Lood C, Gullstrand B, et al. Increased serum levels of S100A8/A9 and S100A12 are associated with cardiovascular disease in patients with inactive systemic lupus erythematosus. Rheumatol. 2013 ; 52: 2048-2055
35. de Leeuw K, Graaff R, de Vries R, et al. Accumulation of advanced glycation endproducts in patients with systemic lupus erythematosus. Rheumatol. 2007 ; 46: 1551-1556
36. Urbonaviciute V, Fürnrohr BG, Meister S, et al. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: Implications for the pathogenesis of SLE. J Exp Med. 2008 ; 205: 3007-3018
37. Santilli F, Vazzana N, Bucciarelli LG, Davi G. Soluble forms of RAGE in human diseases: Clinical and therapeutical implications. Curr Med Chem. 2009 ; 16: 940-952
38. Hreggvidsdottir HS, Ostberg T, Wähämaa H, et al. The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation. J Leukoc Biol. 2009 ; 86: 655-662
39. García-Arnandis I, Guillén MI, Gomar F, et al. High mobility group box 1 potentiates the pro-inflammatory effects of interleukin-1beta in osteoarthritic synoviocytes. Arthritis Res Ther. 2010 ; 12: R165 - R165
40. Tian J, Avalos AM, Mao SY, et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol. 2007 ; 8: 487-496
41. Gigante A, Gasperini ML, Afeltra A, et al. Cytokines expression in SLE nephritis. Eur Rev Med Pharmacol Sci. 2011 ; 15: 15-24
42. Sha Y, Zmijewski J, Xu Z, Abraham E. HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J Immunol. 2008 ; 180: 2531-2537
43. Ivanov S, Dragoi AM, Wang X, et al. A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood. 2007 ; 110: 1970-1981
44. Youn JH, Oh YJ, Kim ES, Choi JE, Shin JS. High mobility group box 1 protein binding to lipopolysaccharide facilitates transfer of lipopolysaccharide to CD14 and enhances lipopolysaccharide-mediated TNF-alpha production in human monocytes. J Immunol. 2008 ; 180: 5067-5074
45. Rouhiainen A, Tumova S, Valmu L, Kalkkinen N, Rauvala H. Pivotal advance: Analysis of proinflammatory activity of highly purified eukaryotic recombinant HMGB1 (amphoterin). J Leukoc Biol. 2007 ; 81: 49-58
46. Andersson U, Wang H, Palmblad K, et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med. 2000 ; 192: 565-570
47. Nogueira-Machado JA, Volpe CM, Veloso CA, Chaves MM. HMGB1, TLR and RAGE: A functional tripod that leads to diabetic inflammation. Expert Opin Ther Targets. 2011 ; 15: 1023-1035
48. Krieg AM. TLR9 and DNA 'feel' RAGE. Nat Immunol. 2007 ; 8: 475-477
49. Nienhuis HL, de Leeuw K, Bijzet J, et al. Skin autofluorescence is increased in systemic lupus erythematosus but is not reflected by elevated plasma levels of advanced glycation endproducts. Rheumatology. 2008 ; 47: 1554-1558
50. Ma CY, Ma JL, Jiao YL, et al. The plasma level of soluble receptor for advanced glycation end products is decreased in patients with systemic lupus erythematosus. Scand J Immunol. 2012 ; 75: 614-622
51. Raucci A, Cugusi S, Antonelli A, et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J. 2008 ; 22: 3716-3727
52. Zhang L, Bukulin M, Kojro E, et al. Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. J Biol Chem. 2008 ; 283: 35507-35516
53. Parkin E, Harris B. A disintegrin and metalloproteinase (ADAM)-mediated ectodomain shedding of ADAM10. J Neurochem. 2009 ; 108: 1464-1479
54. Galichet A, Weibel M, Heizmann CW. Calcium-regulated intramembrane proteolysis of the RAGE receptor. Biochem Biophys Res Commun. 2008 ; 370: 1-5
55. Kwon JH, Kim YH, Kwon JY, Park YW. Clinical significance of serum sRAGE and esRAGE in women with normal pregnancy and preeclampsia. J Perinat Med. 2011 ; 39: 507-513
56. Musumeci D, Roviello GN, Montesarchio D. An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies. Pharmacol Ther. 2014 ; 141: 347-357
57. Sun W, Jiao Y, Cui B, et al. Immune complexes activate human endothelium involving the cell-signaling HMGB1-RAGE axis in the pathogenesis of lupus vasculitis. Lab Invest. 2013 ; 93: 626-638
58. Grossin N, Boulanger E, Wautier MP, Wautier JL. The different isoforms of the receptor for advanced glycation end products are modulated by pharmacological agents. Clin Hemorheol Microcirc. 2010 ; 45: 143-153